FDA
-
-
-
-
-
-
-
Spruce Biosciences names Eric Jordan VP of marketing, Tina Gullotta VP of finance
-
-
-
-
-
-
-
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
-
-
-
-
-
-
-
Spruce Biosciences reports positive long-term data for MPS IIIB therapy
-
-
-
-
-
-
-
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
-
-
-
-
-
-
-
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
-
-
-
-
-
-
-
Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
325,829 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

